Mail-order dominates mifepristone access in telehealth-friendly states, study finds

Mail-order became the main route for mifepristone in states that allow telehealth abortion, even after federal regulators opened the door for retail pharmacies to dispense the pill. A new study in JAMA from University of Southern California researchers found that pharmacies filled about 2,700 mifepristone prescriptions a month since January 2023, but fewer than 2% of those fills in the 27 states and the District of Columbia where telehealth abortion is allowed went through physical retail pharmacies.

The contrast was stark in the states that still permit abortion but restrict telehealth access. In those 11 states, about 61% of mifepristone prescriptions were filled in-store, showing how state policy, not just FDA approval, determines whether patients can actually walk into a pharmacy and leave with the drug. Dima Qato, the USC lead author, said the retail rollout was strikingly small, especially among chains.

The findings underscore how abortion access has split into two systems after the Supreme Court overturned Roe v. Wade in 2022. In places where telehealth remains legal, the pill has largely shifted to mail-order channels. In places where telehealth is blocked or tightly limited, pharmacy counters still play a larger role. The data suggest that the practical front line of abortion care is now geography: legal status, telemedicine rules, and whether a pharmacy is willing to participate.

Mifepristone itself has been on the market since the FDA first approved it in 2000, and it is currently approved for medication abortion through 10 weeks of gestation. In January 2023, the FDA permanently removed the in-person dispensing requirement and created a pharmacy certification pathway under the Mifepristone REMS program, allowing certified retail and mail-order pharmacies to dispense the drug to patients with prescriptions from certified prescribers. The agency also approved a generic version in 2019.

Even with that federal change, the retail presence has remained limited. CVS and Walgreens both received certification in 2024, but Walgreens said its rollout would be phased and that it would not publicly identify dispensing sites. A USC summary tied to the reporting said 92% of retail fills came from independent pharmacies and only 8% from chains, a sign that large pharmacy operators have moved cautiously in a politically charged market. The result is a patchwork in which mifepristone is legally more available than before, but still most often reaches patients by mail in the states where telehealth abortion is allowed.